Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.

"Conflict of Interest Disclosures Naomi Kiyota reports grants from Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, AstraZeneca Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., and Rakuten Medical Inc., and honoraria from Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, Merck Biopharma, AstraZeneca Co., Ltd., Merck Sharp & Dohme Corp., Eisai Co., Ltd., and Bayer AG. Makoto Tahara reports grants and personal fees from Eisai, MSD, Bristol Myers Squibb, Rakuten Medical, Pfizer, AstraZeneca, Bayer, and Ono Pharmaceutical, and personal fees from Merck, Serono, and Loxo. Bruce Robinson reports a leadership role with Cochlear and Mayne Pharma, stock and other ownership interests with Cochlear and Mayne Pharma, a consulting or advisory role with Loxo and Eisai, serving on a speakers' bureau for Eisai, and receiving travel/accommodations/expenses from Eisai. Steven I. Sherman reports honoraria from Eisai, a consulting or advisory role with Exelixis, Loxo, and Lilly, and research funding from Exelixis. Sophie Leboulleux reports participation on tumor boards for Eisai Co., Ltd., and Lilly. Takuya Suzuki is an employee of Eisai Co., Ltd. Min Ren is an employee of Eisai Inc. Kazuma Fushimi is an employee of Eisai Co., Ltd. Lori J. Wirth reports a consulting/advisory role with Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Lilly, Eisai, Exelixis, Genentech, Loxo Oncology, and Merck, and data safety monitoring committees for Iovance Biotherapeutics and PDS Biotechnology Corporation. The other authors made no disclosures."

"Eisai Inc. 10.13039/501100003769; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. 10.13039/100009947"